Diabetes mellitus: An update
description
Transcript of Diabetes mellitus: An update
![Page 1: Diabetes mellitus: An update](https://reader035.fdocuments.us/reader035/viewer/2022062314/568148af550346895db5c4c8/html5/thumbnails/1.jpg)
Diabetes mellitus: An update
D. HuntMarch 2010
![Page 2: Diabetes mellitus: An update](https://reader035.fdocuments.us/reader035/viewer/2022062314/568148af550346895db5c4c8/html5/thumbnails/2.jpg)
Significance of diabetes mellitus
• 5% of the population has diagnosed diabetes
• prevalence increases with age:20 - 44: 1%45 - 65: 5%> 65: 10%
• the true prevalence of diabetes is estimated to be twice the prevalence of diagnosed diabetes
![Page 3: Diabetes mellitus: An update](https://reader035.fdocuments.us/reader035/viewer/2022062314/568148af550346895db5c4c8/html5/thumbnails/3.jpg)
Frequency of diagnosed and undiagnosed diabetes and IGT, by age (U.S. data - Harris)
0
5
10
15
20
25
30
35
40
20-34 35-44 45-54 55-64 65-74
% ofpopulation
IGTUndiagnosed diabetesDiagnosed diabetes
Harris. Diabetes Care 1993;16:642-52.
Significance of diabetes mellitus
![Page 4: Diabetes mellitus: An update](https://reader035.fdocuments.us/reader035/viewer/2022062314/568148af550346895db5c4c8/html5/thumbnails/4.jpg)
Eye Disease
Type 1: 25% after 15 yearsType 2: 4% - 12% after 15 years
Diabetes is the leading cause of adult-onset blindness
![Page 5: Diabetes mellitus: An update](https://reader035.fdocuments.us/reader035/viewer/2022062314/568148af550346895db5c4c8/html5/thumbnails/5.jpg)
Kidney Disease
Type 1: 30% after 15 yearsType 2: 20% after 15 years
Diabetes is the leading cause of end-stage renal disease
![Page 6: Diabetes mellitus: An update](https://reader035.fdocuments.us/reader035/viewer/2022062314/568148af550346895db5c4c8/html5/thumbnails/6.jpg)
Foot complications
Loss of foot sensation > foot ulcers and infections > foot amputations
Amputation rate: 2 - 30/1000 patient-years
Diabetes is the leading cause of non-traumatic amputation
![Page 7: Diabetes mellitus: An update](https://reader035.fdocuments.us/reader035/viewer/2022062314/568148af550346895db5c4c8/html5/thumbnails/7.jpg)
Haffner Am J Cardiol 1999;84:11J-4J.
Framingham study: diabetes and CAD mortality at 20-year follow-up
Cardiovascular Disease Risk is Increased 2 to 4 Times
17.4
8.5
17.0
3.602468
101214161820
Annual CAD Deaths per 1,000
Persons
Men Women
Diabetics Nondiabetics
![Page 8: Diabetes mellitus: An update](https://reader035.fdocuments.us/reader035/viewer/2022062314/568148af550346895db5c4c8/html5/thumbnails/8.jpg)
Blood glucose control reduces the risk of diabetic
complications, especially microvascular complications
UK Prospective Diabetes UK Prospective Diabetes StudyStudy
![Page 9: Diabetes mellitus: An update](https://reader035.fdocuments.us/reader035/viewer/2022062314/568148af550346895db5c4c8/html5/thumbnails/9.jpg)
UK Prospective Diabetes Study
20-year Interventional Trial from 1977 to 1997:
5,102 patients with newly-diagnosed DM2
Median follow-up 10.0 years, range 6 to 20 years
Results presented in 1998
![Page 10: Diabetes mellitus: An update](https://reader035.fdocuments.us/reader035/viewer/2022062314/568148af550346895db5c4c8/html5/thumbnails/10.jpg)
Microvascular EndpointsMicrovascular Endpoints
p=0.0099
0%
10%
20%
30%
0 3 6 9 12 15
% o
f pa
tient
s w
ith a
n ev
ent
Years from randomisation
Intensive
Conventional
Risk reduction 25%(95% CI: 7% to 40%)
renal failure or death, vitreous haemorrhage or photocoagulation346 of 3867 patients (9%)
![Page 11: Diabetes mellitus: An update](https://reader035.fdocuments.us/reader035/viewer/2022062314/568148af550346895db5c4c8/html5/thumbnails/11.jpg)
Myocardial InfarctionMyocardial Infarction
0%
10%
20%
30%
0 3 6 9 12 15
% o
f pa
tient
s w
ith a
n ev
ent
Years from randomisation
Intensive
Conventional
p=0.052
Risk reduction 16%(95% CI: 0% to 29%)
fatal or non fatal myocardial infarction, sudden death573 of 3867 patients (15%)
![Page 12: Diabetes mellitus: An update](https://reader035.fdocuments.us/reader035/viewer/2022062314/568148af550346895db5c4c8/html5/thumbnails/12.jpg)
UK Prospective Diabetes Study
20-year Interventional Trial from 1977 to 1997 5,102 patients with newly-diagnosed DM2
Median follow-up 10.0 years, range 6 to 20 years
Results presented in 1998
10-year Post-Trial Monitoring from 1997 to 2007 Annual follow-up of the survivor cohort
Clinic-based for first five years
Questionnaire-based for last five years
Median overall follow-up 17.0 years, range 16 to 30 years
![Page 13: Diabetes mellitus: An update](https://reader035.fdocuments.us/reader035/viewer/2022062314/568148af550346895db5c4c8/html5/thumbnails/13.jpg)
Post-Trial Changes in HbA1c
UKPDS resultspresented
![Page 14: Diabetes mellitus: An update](https://reader035.fdocuments.us/reader035/viewer/2022062314/568148af550346895db5c4c8/html5/thumbnails/14.jpg)
Microvascular Disease
Intensive (SU/Ins) vs. Conventional glucose control
(photocoagulation, vitreous haemorrhage, renal failure)
HR (95%CI)
![Page 15: Diabetes mellitus: An update](https://reader035.fdocuments.us/reader035/viewer/2022062314/568148af550346895db5c4c8/html5/thumbnails/15.jpg)
Myocardial Infarction(fatal or non-fatal myocardial infarction or sudden death)
Intensive (SU/Ins) vs. Conventional glucose control
![Page 16: Diabetes mellitus: An update](https://reader035.fdocuments.us/reader035/viewer/2022062314/568148af550346895db5c4c8/html5/thumbnails/16.jpg)
All-cause Mortality
Intensive (SU/Ins) vs. Conventional glucose control
HR (95%CI)
![Page 17: Diabetes mellitus: An update](https://reader035.fdocuments.us/reader035/viewer/2022062314/568148af550346895db5c4c8/html5/thumbnails/17.jpg)
After median 8.5 years post-trial follow-up
Aggregate Endpoint 1997 2007
Any diabetes related endpoint RRR: 12% 9% P: 0.029 0.040
Microvascular disease RRR: 25% 24% P: 0.0099 0.001
Myocardial infarction RRR: 16% 15% P: 0.052 0.014
All-cause mortality RRR: 6% 13% P: 0.44 0.007
RRR = Relative Risk Reduction, P = Log Rank
Legacy Effect of Earlier Glucose Control
![Page 18: Diabetes mellitus: An update](https://reader035.fdocuments.us/reader035/viewer/2022062314/568148af550346895db5c4c8/html5/thumbnails/18.jpg)
After median 8.8 years post-trial follow-up
Aggregate Endpoint 1997 2007
Any diabetes related endpoint RRR: 32% 21% P: 0.0023 0.013
Microvascular disease RRR: 29% 16% P: 0.19 0.31
Myocardial infarction RRR: 39% 33% P: 0.010 0.005
All-cause mortality RRR: 36% 27% P: 0.011 0.002
RRR = Relative Risk Reduction, P = Log Rank
Legacy Effect of Earlier Metformin Therapy
![Page 19: Diabetes mellitus: An update](https://reader035.fdocuments.us/reader035/viewer/2022062314/568148af550346895db5c4c8/html5/thumbnails/19.jpg)
• Despite an early loss of glycemic differences, a continued reduction in microvascular risk and emergent risk reductions for MI and death were observed during 10 years of post-trial follow-up
UKPDS Conclusions
![Page 20: Diabetes mellitus: An update](https://reader035.fdocuments.us/reader035/viewer/2022062314/568148af550346895db5c4c8/html5/thumbnails/20.jpg)
![Page 21: Diabetes mellitus: An update](https://reader035.fdocuments.us/reader035/viewer/2022062314/568148af550346895db5c4c8/html5/thumbnails/21.jpg)
Pharmacologic Management of Type 2 Diabetes
• If glycemic targets are not achieved within 2 to 3 months of lifestyle management, pharmacotherapy should be initiated.
• Timely adjustments should be made to attain target A1C within 6 to 12 months.
• In patients with marked hyperglycemia (A1C ≥ 9.0%), pharmacotherapy should be initiated concomitantly with lifestyle management, and consideration be given to either combination therapy or insulin.
![Page 22: Diabetes mellitus: An update](https://reader035.fdocuments.us/reader035/viewer/2022062314/568148af550346895db5c4c8/html5/thumbnails/22.jpg)
Management of hyperglycemia in type 2 diabetes
A1C >9.0% Symptomatic with metabolic decompensation
A1C <9.0%
Initiate pharmacotherapy immediately without waiting for effect from lifestyle interventions:
• Consider initiating metformin concurrently with another agent from a different class or
• Initiate insulin
Initiate metformin Initiate insulin ± metformin
If not at target
L
I
F
E
S T Y L E
Clinical Assessment
Lifestyle intervention (initiation of nutrition therapy and physical activity)
![Page 23: Diabetes mellitus: An update](https://reader035.fdocuments.us/reader035/viewer/2022062314/568148af550346895db5c4c8/html5/thumbnails/23.jpg)
Oral agents:(agents listed in alphabetical order)
Class A1C Hypoglyc. Advantages Disadvantages
Alpha-glucos. inhibitor
↓ Rare Improved postprandial control weight neutral
GI side effects
Incretin: DPP-4 inhib.
↓ - ↓↓
Rare Improved postprandial control; weight neutral
New agents (unknown long-term safety)
Insulin ↓-↓↓↓
Yes No dose ceiling Weight gain
Meglitinides
Sulfonylureas
↓ - ↓↓
↓↓
Yes
Yes
Improved postprandial controlNewer sulfonylureas (gliclazide) are associated with less hypoglycemia than glyburide
Requires TID to QID dosing
Weight gain
*less hypoglycemia in the context of missed meals
TZD ↓ ↓ Rare Durable monotherapy
6-12 weeks for maximal effectEdema, rare CHF, fractures in females
↓ = < 1.0% decrease in A1C
↓ ↓ = 1.0–2.0% decrease in A1C
↓ ↓ ↓ = >2.0% decrease in A1COral agents beyond metformin
![Page 24: Diabetes mellitus: An update](https://reader035.fdocuments.us/reader035/viewer/2022062314/568148af550346895db5c4c8/html5/thumbnails/24.jpg)
If not at target
• Add another drug from a different class; or • Add bedtime basal insulin to other agent(s); or• Intensify insulin regimen
Timely adjustment to and/or addition of antihyperglycemic agents should be made to attain target
A1C within 6 to 12 months
Canadian Diabetes Association 2008 Clinical Practice Guidelines for the Prevention and Management of Diabetes in Canada; Canadian Journal of Diabetes: 2008 Vol:32 Supplement
![Page 25: Diabetes mellitus: An update](https://reader035.fdocuments.us/reader035/viewer/2022062314/568148af550346895db5c4c8/html5/thumbnails/25.jpg)
Natural History of Type 2 Diabetes
Normal Impaired glucosetolerance
Type 2 diabetes
Time
Insulinresistance
Insulinproduction
Glucoselevel
b-celldysfunction
Henry. Am J Med 1998;105(1A):20S-6S.
![Page 26: Diabetes mellitus: An update](https://reader035.fdocuments.us/reader035/viewer/2022062314/568148af550346895db5c4c8/html5/thumbnails/26.jpg)
b cell function in type 2 diabetic patients
Natural deterioration of Natural deterioration of bb-cell function-cell function
Years after diagnosis
b-cell
fun
cti
on
![Page 27: Diabetes mellitus: An update](https://reader035.fdocuments.us/reader035/viewer/2022062314/568148af550346895db5c4c8/html5/thumbnails/27.jpg)
Insulin
Type Starts Peaks Duration
Lispro
Aspart
Glulisine
5-10 min 0.5-1 hrs 3.5 hrs
Regular
Toronto
30 min 2-4 hrs 6-8 hrs
N/NPH 1-2 hrs 6-10 hrs 16-24 hrs
Detemir - 6 – 8 hrs Up to 24 hrs
Glargine 1.5 hrs None Up to 24 hrs
![Page 28: Diabetes mellitus: An update](https://reader035.fdocuments.us/reader035/viewer/2022062314/568148af550346895db5c4c8/html5/thumbnails/28.jpg)
Insulin regimens – Type 2 DM
Many different potential regimens!
– Oral + hs insulin (basal)– Oral + AM insulin (basal)– Pre-mixed insulin with breakfast and
supper– Short-acting with meals + bedtime basal
![Page 29: Diabetes mellitus: An update](https://reader035.fdocuments.us/reader035/viewer/2022062314/568148af550346895db5c4c8/html5/thumbnails/29.jpg)
Holman RR. NEJM 2009;361:1736-47
![Page 30: Diabetes mellitus: An update](https://reader035.fdocuments.us/reader035/viewer/2022062314/568148af550346895db5c4c8/html5/thumbnails/30.jpg)
Aims
First Phase
One-year head-to-head comparison of the efficacy of three different types of analogue insulins, when given in addition to dual oral antidiabetic therapy:
Biphasic insulin
Prandial insulin
Basal insulin
![Page 31: Diabetes mellitus: An update](https://reader035.fdocuments.us/reader035/viewer/2022062314/568148af550346895db5c4c8/html5/thumbnails/31.jpg)
Patient Disposition
235Assigned to
biphasic insulin(biphasic aspart)
234Assigned to basal
insulin(detemir)
239Assigned to
prandial insulin(aspart)
34 Discontinued
45 Discontinued51Discontinued
201 (86%)Completedthree years
189 (81%)Completedthree years
188 (79%)Completedthree years
Overall, 18.4% of patients did not complete three years No difference in proportions between groups (p=0.15) No difference in baseline characteristics between those who
completed or did not complete three years follow up
![Page 32: Diabetes mellitus: An update](https://reader035.fdocuments.us/reader035/viewer/2022062314/568148af550346895db5c4c8/html5/thumbnails/32.jpg)
Transition to a Complex Insulin Regimen
* Intensify to a complex insulin regimen in year one if unacceptable hyperglycaemia
708 T2DMon dual
oral agents
Add biphasic insulin*twice a day
Add prandial insulin*three times a day
R
First Phase
Add basal insulin*once (or twice) daily
Add prandial insulinat midday
Add basal insulinbefore bed
Second Phase
Add prandial insulinthree times a day
From one year onwards, if HbA1c levels were >6.5%, sulfonylurea therapy was stopped and a second type of insulin was added
![Page 33: Diabetes mellitus: An update](https://reader035.fdocuments.us/reader035/viewer/2022062314/568148af550346895db5c4c8/html5/thumbnails/33.jpg)
Demographic CharacteristicsBiphasic
N=235PrandialN=239
BasalN=234
Male 68% 64% 61%
White Caucasian 94% 90% 93%
*Diabetes duration (yrs) 9 (6-12) 9 (6-14) 9 (6-12)
Taking sulfonylurea 98% 100% 99%
Taking metformin 96% 95% 97%
Age (years) 61.7±8.9 61.6 ±10.5 61.9±10.0
Body mass index (kg/m2) 30.2 ±4.8 29.6 ±4.5 29.7 ±4.6
HbA1c (%) 8.6 ±0.8 8.6 ±0.8 8.4 ±0.8
*interquartile range No significant differences between groups
![Page 34: Diabetes mellitus: An update](https://reader035.fdocuments.us/reader035/viewer/2022062314/568148af550346895db5c4c8/html5/thumbnails/34.jpg)
Glycaemic targets and Insulin Injections
Fasting and pre-meal: 4.0-5.5 mmol/l (72-99 mg/dl)
Two-hours post meal: 5.0-7.0 mmol/l (90-126 mg/dl)
6 6 1212 624186 6 1212 624186 6 1212 62418
Biphasic
Basal
Prandial*
* Twice a day if required
![Page 35: Diabetes mellitus: An update](https://reader035.fdocuments.us/reader035/viewer/2022062314/568148af550346895db5c4c8/html5/thumbnails/35.jpg)
Complex Insulin Regimens
Proportion eligible for a second type of insulin per protocol
Proportion taking two types of insulin
![Page 36: Diabetes mellitus: An update](https://reader035.fdocuments.us/reader035/viewer/2022062314/568148af550346895db5c4c8/html5/thumbnails/36.jpg)
Insulin Doses Over 3 YearsMedian±95% confidence interval
Biphasic±prandial
Prandial±basal
Basal±prandial
![Page 37: Diabetes mellitus: An update](https://reader035.fdocuments.us/reader035/viewer/2022062314/568148af550346895db5c4c8/html5/thumbnails/37.jpg)
Total Daily Insulin Doses at 3 YearsMedian±95% confidence interval
![Page 38: Diabetes mellitus: An update](https://reader035.fdocuments.us/reader035/viewer/2022062314/568148af550346895db5c4c8/html5/thumbnails/38.jpg)
HbA1c Values Over 3 YearsMedian±95% confidence interval
Biphasic±prandial
Prandial±basal
Basal±prandial
Overall6.9%
(6.8 to 7.1)
![Page 39: Diabetes mellitus: An update](https://reader035.fdocuments.us/reader035/viewer/2022062314/568148af550346895db5c4c8/html5/thumbnails/39.jpg)
Primary Outcome: HbA1c at 3 YearsMedian±95% confidence interval
![Page 40: Diabetes mellitus: An update](https://reader035.fdocuments.us/reader035/viewer/2022062314/568148af550346895db5c4c8/html5/thumbnails/40.jpg)
Body Weight over 3 YearsMedian±95% confidence interval
Biphasic±prandial
Prandial±basal
Basal±prandial
![Page 41: Diabetes mellitus: An update](https://reader035.fdocuments.us/reader035/viewer/2022062314/568148af550346895db5c4c8/html5/thumbnails/41.jpg)
Increase in Body Weight Over 3 YearsMean±1SD
![Page 42: Diabetes mellitus: An update](https://reader035.fdocuments.us/reader035/viewer/2022062314/568148af550346895db5c4c8/html5/thumbnails/42.jpg)
Hypoglycaemia
Categorised as
Grade 1- Symptoms only with glucose (if measured) ≥3.1 mmol/l (≥56 mg/dl)
Grade 2- Symptoms plus glucose <3.1 mmol/l (<56 mg/dl)
Grade 3- Third party assistance required
![Page 43: Diabetes mellitus: An update](https://reader035.fdocuments.us/reader035/viewer/2022062314/568148af550346895db5c4c8/html5/thumbnails/43.jpg)
Grade 2 or 3 Hypoglycaemia Over 3 Years
Biphasic±prandial
Prandial±basal
Basal±prandial
![Page 44: Diabetes mellitus: An update](https://reader035.fdocuments.us/reader035/viewer/2022062314/568148af550346895db5c4c8/html5/thumbnails/44.jpg)
Grade 2 or 3 Hypoglycaemia Over 3 Years
Allpatients
Patients withHbA1c ≤6.5%
![Page 45: Diabetes mellitus: An update](https://reader035.fdocuments.us/reader035/viewer/2022062314/568148af550346895db5c4c8/html5/thumbnails/45.jpg)
Overview of Main Results
Biphasic Prandial Basal
Fewer hypoglycaemic episodes ++ + +++Less weight gain + + ++Less increase in waist circumference
+ + ++
![Page 46: Diabetes mellitus: An update](https://reader035.fdocuments.us/reader035/viewer/2022062314/568148af550346895db5c4c8/html5/thumbnails/46.jpg)
4T trial
Three quarters of patients added a second insulin Those commencing therapy with a basal or prandial
insulin more often achieved glycaemic targets than patients commencing with a biphasic insulin
Patients commencing therapy with basal insulin had fewer hypoglycaemic episodes and less weight gain
These findings provide clear evidence in people with type 2 diabetes to support starting insulin therapy with a once a day basal insulin, and then adding
a mealtime insulin if glycaemic targets are not met
![Page 47: Diabetes mellitus: An update](https://reader035.fdocuments.us/reader035/viewer/2022062314/568148af550346895db5c4c8/html5/thumbnails/47.jpg)
Beyond Glycemic Control
Blood pressure control
Lipid therapy
Microvascular complication screening and management
![Page 48: Diabetes mellitus: An update](https://reader035.fdocuments.us/reader035/viewer/2022062314/568148af550346895db5c4c8/html5/thumbnails/48.jpg)
Blood Pressure Control Study
UK Prospective Diabetes StudyUK Prospective Diabetes Study
![Page 49: Diabetes mellitus: An update](https://reader035.fdocuments.us/reader035/viewer/2022062314/568148af550346895db5c4c8/html5/thumbnails/49.jpg)
Randomisation
on antihypertensive therapyn = 421
not on antihypertensive therapyn = 727
avoid ACE inhibitor : Beta blockern = 390
34%
less tight blood pressure controlaim : BP < 180/105 mmHg
ACE inhibitorn = 400
35%
Beta blockern = 358
31%
tight blood pressure controlaim : BP < 150 / 85 mmHg
randomisation
1148 hypertensive patients
![Page 50: Diabetes mellitus: An update](https://reader035.fdocuments.us/reader035/viewer/2022062314/568148af550346895db5c4c8/html5/thumbnails/50.jpg)
Blood Pressure : Tight vs Less Tight Control
60
80
100
140
160
180
0 2 4 6 8
mm
Hg
Years from randomisation
cohort, median values
Less tight control Tight control
![Page 51: Diabetes mellitus: An update](https://reader035.fdocuments.us/reader035/viewer/2022062314/568148af550346895db5c4c8/html5/thumbnails/51.jpg)
Any diabetes-related endpoints
0%
10%
20%
30%
40%
50%
0 3 6 9
% o
f pa
tient
s w
ith e
vent
s
Years from randomisation
Tight blood pressure control (758)
Less tight blood pressure control (390)
risk reduction24% p=0.0046
![Page 52: Diabetes mellitus: An update](https://reader035.fdocuments.us/reader035/viewer/2022062314/568148af550346895db5c4c8/html5/thumbnails/52.jpg)
Diabetes-related deaths
0%
5%
10%
15%
20%
0 3 6 9
% o
f pa
tient
s w
ith e
vent
s
Years from randomisation
Tight blood pressure control (758)
Less tight blood pressure control (390)
risk reduction32% p=0.019
![Page 53: Diabetes mellitus: An update](https://reader035.fdocuments.us/reader035/viewer/2022062314/568148af550346895db5c4c8/html5/thumbnails/53.jpg)
Any DM-related endpoint 24% p=0.0046
Diabetes-related deaths 32% p=0.019
Stroke 44% p=0.013
Microvascular disease 37% p=0.0092
Heart failure 56% p=0.0043
Retinopathy progression 34% p=0.0038
Deterioration of vision 47% p=0.0036
Blood Pressure Control Study
![Page 54: Diabetes mellitus: An update](https://reader035.fdocuments.us/reader035/viewer/2022062314/568148af550346895db5c4c8/html5/thumbnails/54.jpg)
Blood Pressure Study
ACCORDACCORD
ACCORD Study Group. NEJM 2010
![Page 55: Diabetes mellitus: An update](https://reader035.fdocuments.us/reader035/viewer/2022062314/568148af550346895db5c4c8/html5/thumbnails/55.jpg)
![Page 56: Diabetes mellitus: An update](https://reader035.fdocuments.us/reader035/viewer/2022062314/568148af550346895db5c4c8/html5/thumbnails/56.jpg)
![Page 57: Diabetes mellitus: An update](https://reader035.fdocuments.us/reader035/viewer/2022062314/568148af550346895db5c4c8/html5/thumbnails/57.jpg)
ACCORD BP TrialACCORD BP Trial
ACCORD Study Group. NEJM 2010
4,733 patients with DM2; high CVS risk
SBP 130 – 180
Randomized to target SBP <140 v. <120
Primary outcome: nonfatal MI, nonfatal CVA; CVS death
Follow-up: 4.7 years; 95% complete
![Page 58: Diabetes mellitus: An update](https://reader035.fdocuments.us/reader035/viewer/2022062314/568148af550346895db5c4c8/html5/thumbnails/58.jpg)
Baseline Characteristics
<120 <140
N 2362 2371
Age 62 62
% females 48% 48%
Hx CVS event 34% 33%
SBP 139.0 139.4
Duration DM 9 10
GHb (%) 8.4 8.3
![Page 59: Diabetes mellitus: An update](https://reader035.fdocuments.us/reader035/viewer/2022062314/568148af550346895db5c4c8/html5/thumbnails/59.jpg)
![Page 60: Diabetes mellitus: An update](https://reader035.fdocuments.us/reader035/viewer/2022062314/568148af550346895db5c4c8/html5/thumbnails/60.jpg)
ACCORD BP TrialACCORD BP Trial
ACCORD Study Group. NEJM 2010
Achieved SBP: 119 v. 133
Antihypertensive medications: 3.4 v. 2.3
![Page 61: Diabetes mellitus: An update](https://reader035.fdocuments.us/reader035/viewer/2022062314/568148af550346895db5c4c8/html5/thumbnails/61.jpg)
ACCORD BP TrialACCORD BP Trial
ACCORD Study Group. NEJM 2010
Achieved SBP: 119 v. 133
Antihypertensive medications: 3.4 v. 2.3
Primary outcome:
Nonfatal MI, nonfatal CVA, CVS death (%/year):
1.9% v. 2.1%; HR 0.88 (0.73 – 1.06, p=0.20)
![Page 62: Diabetes mellitus: An update](https://reader035.fdocuments.us/reader035/viewer/2022062314/568148af550346895db5c4c8/html5/thumbnails/62.jpg)
ACCORD BP Trial: OutcomesACCORD BP Trial: Outcomes
ACCORD Study Group. NEJM 2010
Nonfatal MI, nonfatal CVA, CVS death (%/year):
1.9% v. 2.1%; HR 0.88 (0.73 – 1.06, p=0.20)
Total mortality: 1.3% v. 1.2%, p=0.55
CVS death: 0.5% v. 0.5%
Stroke: 0.3% v. 0.5%, p=0.01
![Page 63: Diabetes mellitus: An update](https://reader035.fdocuments.us/reader035/viewer/2022062314/568148af550346895db5c4c8/html5/thumbnails/63.jpg)
![Page 64: Diabetes mellitus: An update](https://reader035.fdocuments.us/reader035/viewer/2022062314/568148af550346895db5c4c8/html5/thumbnails/64.jpg)
![Page 65: Diabetes mellitus: An update](https://reader035.fdocuments.us/reader035/viewer/2022062314/568148af550346895db5c4c8/html5/thumbnails/65.jpg)
ACCORD BP Trial: ConclusionACCORD BP Trial: Conclusion
ACCORD Study Group. NEJM 2010
Targeting a SBP < 120, as compared to a SBP < 140, does not improve CVS outcomes in patients with DM2 at high risk of CVS events
![Page 66: Diabetes mellitus: An update](https://reader035.fdocuments.us/reader035/viewer/2022062314/568148af550346895db5c4c8/html5/thumbnails/66.jpg)
Lipid Therapy Study
ACCORDACCORD
ACCORD Study Group. NEJM 2010
![Page 67: Diabetes mellitus: An update](https://reader035.fdocuments.us/reader035/viewer/2022062314/568148af550346895db5c4c8/html5/thumbnails/67.jpg)
![Page 68: Diabetes mellitus: An update](https://reader035.fdocuments.us/reader035/viewer/2022062314/568148af550346895db5c4c8/html5/thumbnails/68.jpg)
ACCORD Lipid TrialACCORD Lipid Trial
ACCORD Study Group. NEJM 2010
5,518 patients with DM2; high CVS risk
LDL 1.5 – 4.6; HDL < 1.4; TG < 8.5
All patients received open label simvastatin
Randomized to fenofibrate (160 mg) v. placebo
Primary outcome: nonfatal MI, nonfatal CVA; CVS death
Follow-up: 4.7 years
![Page 69: Diabetes mellitus: An update](https://reader035.fdocuments.us/reader035/viewer/2022062314/568148af550346895db5c4c8/html5/thumbnails/69.jpg)
Baseline Characteristics
Fenofibrate Placebo
N 2765 2753
Age 62 62
% females 31% 31%
Hx CVS event 36% 37%
LDL 2.6 2.6
HDL 1.0 1.0
TG 2.1 2.1
![Page 70: Diabetes mellitus: An update](https://reader035.fdocuments.us/reader035/viewer/2022062314/568148af550346895db5c4c8/html5/thumbnails/70.jpg)
![Page 71: Diabetes mellitus: An update](https://reader035.fdocuments.us/reader035/viewer/2022062314/568148af550346895db5c4c8/html5/thumbnails/71.jpg)
ACCORD Lipid TrialACCORD Lipid Trial
ACCORD Study Group. NEJM 2010
Achieved LDL: 2.1 v. 2.1
Achieved HDL: 1.1 v. 1.0
Achieved TG: 1.7 v. 1.9
![Page 72: Diabetes mellitus: An update](https://reader035.fdocuments.us/reader035/viewer/2022062314/568148af550346895db5c4c8/html5/thumbnails/72.jpg)
ACCORD Lipid TrialACCORD Lipid Trial
ACCORD Study Group. NEJM 2010
Achieved LDL: 2.1 v. 2.1
Achieved HDL: 1.1 v. 1.0
Achieved TG: 1.7 v. 1.9
Primary outcome:
Nonfatal MI, nonfatal CVA, CVS death (%/year):
2.2% v. 2.4%; HR 0.92 (0.79 – 1.08, p=0.32)
• Total mortality: 1.5% v. 1.6%, p=0.33
![Page 73: Diabetes mellitus: An update](https://reader035.fdocuments.us/reader035/viewer/2022062314/568148af550346895db5c4c8/html5/thumbnails/73.jpg)
ACCORD Lipid Trial: OutcomesACCORD Lipid Trial: Outcomes
ACCORD Study Group. NEJM 2010
Pre-specified subgroups:
Sex:
Men: 11.2% v. 13.3%
Women: 9.1% v. 6.6%, p=.01
Dyslipidemia (HDL<0.9, TG > 2.3):
Dyslipidemia patients: 12.4% v. 17.3%
Non-dyslipidemic patients: 10.1% v. 10.1%, p=.057
![Page 74: Diabetes mellitus: An update](https://reader035.fdocuments.us/reader035/viewer/2022062314/568148af550346895db5c4c8/html5/thumbnails/74.jpg)
ACCORD Lipid Trial: ConclusionsACCORD Lipid Trial: Conclusions
ACCORD Study Group. NEJM 2010
Routine fenofibrate therapy, in addition to simvastatin, does not improve CVS outcomes in patients with DM2 at high risk of CVS events
Addition of fenofibrate to simvastatin may benefit patients with significant dyslipidemia
![Page 75: Diabetes mellitus: An update](https://reader035.fdocuments.us/reader035/viewer/2022062314/568148af550346895db5c4c8/html5/thumbnails/75.jpg)
• Glycemic control
• BP control
• Lipid management
Conclusions